<VariationArchive VariationID="1312504" VariationName="NM_000156.6(GAMT):c.609dup (p.Arg204fs)" VariationType="Duplication" Accession="VCV001312504" Version="3" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-06-23" DateCreated="2022-02-01" MostRecentSubmission="2022-07-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1302765" VariationID="1312504">
      <GeneList>
        <Gene Symbol="GAMT" FullName="guanidinoacetate N-methyltransferase" GeneID="2593" HGNC_ID="HGNC:4136" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>19p13.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="1397026" stop="1401542" display_start="1397026" display_stop="1401542" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="1397024" stop="1401568" display_start="1397024" display_stop="1401568" Strand="-" />
          </Location>
          <OMIM>601240</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000156.6(GAMT):c.609dup (p.Arg204fs)</Name>
      <CanonicalSPDI>NC_000019.10:1397460:CC:CCC</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>19p13.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="1397460" stop="1397461" display_start="1397460" display_stop="1397461" variantLength="1" positionVCF="1397460" referenceAlleleVCF="T" alternateAlleleVCF="TC" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="1397459" stop="1397460" display_start="1397459" display_stop="1397460" variantLength="1" positionVCF="1397459" referenceAlleleVCF="T" alternateAlleleVCF="TC" />
      </Location>
      <OtherNameList>
        <Name>NM_000156.6:c.609dup</Name>
      </OtherNameList>
      <ProteinChange>R204fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000019.10" sequenceAccession="NC_000019" sequenceVersion="10" change="g.1397462dup" Assembly="GRCh38">
            <Expression>NC_000019.10:g.1397462dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000019.9" sequenceAccession="NC_000019" sequenceVersion="9" change="g.1397461dup" Assembly="GRCh37">
            <Expression>NC_000019.9:g.1397461dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008283.1" sequenceAccession="NG_008283" sequenceVersion="1" change="g.18579dup">
            <Expression>NG_008283.1:g.18579dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009785.1" sequenceAccession="NG_009785" sequenceVersion="1" change="g.9093dup">
            <Expression>NG_009785.1:g.9093dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000156.6" sequenceAccession="NM_000156" sequenceVersion="6" change="c.609dup" MANESelect="true">
            <Expression>NM_000156.6:c.609dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000147.1" sequenceAccession="NP_000147" sequenceVersion="1" change="p.Arg204fs">
            <Expression>NP_000147.1:p.Arg204fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="Allelic variant" ID="601240.0006" DB="OMIM" />
        <XRef Type="rs" ID="745740974" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000156.6(GAMT):c.609dup (p.Arg204fs) AND Cerebral creatine deficiency syndrome" Accession="RCV001761398" Version="4">
        <ClassifiedConditionList TraitSetID="16862">
          <ClassifiedCondition DB="MedGen" ID="C5244016">Cerebral creatine deficiency syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-11-02" SubmissionCount="1">Uncertain significance</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000156.6(GAMT):c.609dup (p.Arg204fs) AND Deficiency of guanidinoacetate methyltransferase" Accession="RCV002260948" Version="1">
        <ClassifiedConditionList TraitSetID="2278">
          <ClassifiedCondition DB="MedGen" ID="C0574080">Deficiency of guanidinoacetate methyltransferase</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2022-06-23" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-11-02" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2022-02-01" MostRecentSubmission="2022-07-09">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Uncertain significance</Description>
        <Citation Type="general">
          <ID Source="PubMed">34389248</ID>
        </Citation>
        <DescriptionHistory Dated="2022-07-08">
          <Description>Uncertain significance</Description>
        </DescriptionHistory>
        <DescriptionHistory Dated="2022-07-08">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="16862" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="16661" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Cerebral creatine deficiency syndrome</ElementValue>
                <XRef ID="MONDO:0000456" DB="MONDO" />
                <XRef Type="Phenotypic series" ID="PS300352" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Creatine deficiency syndromes</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">CDS</ElementValue>
                <XRef ID="79172" DB="Orphanet" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">CCAD</ElementValue>
                <XRef ID="NBK3794" DB="GeneReviews" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="18952" />
                <XRef ID="18952" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">The creatine deficiency disorders (CDDs), inborn errors of creatine metabolism and transport, comprise three disorders: the creatine biosynthesis disorders guanidinoacetate methyltransferase (GAMT) deficiency and L-arginine:glycine amidinotransferase (AGAT) deficiency; and creatine transporter (CRTR) deficiency. Developmental delay and cognitive dysfunction or intellectual disability and speech-language disorder are common to all three CDDs. Onset of clinical manifestations of GAMT deficiency (reported in ~130 individuals) is between ages three months and two years; in addition to developmental delays, the majority of individuals have epilepsy and develop a behavior disorder (e.g., hyperactivity, autism, or self-injurious behavior), and about 30% have movement disorder. AGAT deficiency has been reported in 16 individuals; none have had epilepsy or movement disorders. Clinical findings of CRTR deficiency in affected males (reported in ~130 individuals) in addition to developmental delays include epilepsy (variable seizure types and may be intractable) and behavior disorders (e.g., attention deficit and/or hyperactivity, autistic features, impulsivity, social anxiety), hypotonia, and (less commonly) a movement disorder. Poor weight gain with constipation and prolonged QTc on EKG have been reported. While mild-to-moderate intellectual disability is commonly observed up to age four years, the majority of adult males with CRTR deficiency have been reported to have severe intellectual disability. Females heterozygous for CRTR deficiency are typically either asymptomatic or have mild intellectual disability, although a more severe phenotype resembling the male phenotype has been reported.</Attribute>
                <XRef ID="NBK3794" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301745</ID>
                <ID Source="BookShelf">NBK3794</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23519317</ID>
              </Citation>
              <XRef ID="79172" DB="Orphanet" />
              <XRef ID="C5244016" DB="MedGen" />
              <XRef ID="MONDO:0000456" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS300352" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="2278" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="2252" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Deficiency of guanidinoacetate methyltransferase</ElementValue>
                <XRef ID="Guanidinoacetate+Methyltransferase+Deficiency/3202" DB="Genetic Alliance" />
                <XRef ID="124239003" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CEREBRAL CREATINE DEFICIENCY SYNDROME 2</ElementValue>
                <XRef Type="MIM" ID="612736" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0006" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0002" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0003" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0008" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0007" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0004" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0005" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CCDS2</ElementValue>
                <XRef Type="MIM" ID="612736" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2578" />
                <XRef ID="2578" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">The creatine deficiency disorders (CDDs), inborn errors of creatine metabolism and transport, comprise three disorders: the creatine biosynthesis disorders guanidinoacetate methyltransferase (GAMT) deficiency and L-arginine:glycine amidinotransferase (AGAT) deficiency; and creatine transporter (CRTR) deficiency. Developmental delay and cognitive dysfunction or intellectual disability and speech-language disorder are common to all three CDDs. Onset of clinical manifestations of GAMT deficiency (reported in ~130 individuals) is between ages three months and two years; in addition to developmental delays, the majority of individuals have epilepsy and develop a behavior disorder (e.g., hyperactivity, autism, or self-injurious behavior), and about 30% have movement disorder. AGAT deficiency has been reported in 16 individuals; none have had epilepsy or movement disorders. Clinical findings of CRTR deficiency in affected males (reported in ~130 individuals) in addition to developmental delays include epilepsy (variable seizure types and may be intractable) and behavior disorders (e.g., attention deficit and/or hyperactivity, autistic features, impulsivity, social anxiety), hypotonia, and (less commonly) a movement disorder. Poor weight gain with constipation and prolonged QTc on EKG have been reported. While mild-to-moderate intellectual disability is commonly observed up to age four years, the majority of adult males with CRTR deficiency have been reported to have severe intellectual disability. Females heterozygous for CRTR deficiency are typically either asymptomatic or have mild intellectual disability, although a more severe phenotype resembling the male phenotype has been reported.</Attribute>
                <XRef ID="NBK3794" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301745</ID>
                <ID Source="BookShelf">NBK3794</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/GAMT.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Increased Guanidinoacetate, Guanidinoacetate Methyltransferase Deficiency, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/GAMT-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics Algorithm, GAMT Deficiency: Elevated Guanidinoacetate, 2022</CitationText>
              </Citation>
              <XRef ID="382" DB="Orphanet" />
              <XRef ID="C0574080" DB="MedGen" />
              <XRef ID="MONDO:0012999" DB="MONDO" />
              <XRef Type="MIM" ID="612736" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="3896943" SubmissionDate="2021-11-02" DateLastUpdated="2022-02-01" DateCreated="2021-11-06">
        <ClinVarSubmissionID localKey="9f2d4aa2-7db1-43a0-b114-a291b93838b4" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001999904" DateUpdated="2022-02-01" DateCreated="2021-11-06" Type="SCV" Version="2" SubmitterName="Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard" OrgID="506627" OrganizationCategory="laboratory" OrgAbbreviation="Broad RDG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-11-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Uncertain significance</GermlineClassification>
          <Comment>The p.Arg204GlufsTer63 variant in GAMT has been reported in 1 homozygous individual with cerebral creatine deficiency syndrome (PMID: 27848944) and has been identified in in 0.0009% (1/112488) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs745740974). Although this variant has been seen in the general population in a heterozygous state, its frequency is low enough to be consistent with a recessive carrier frequency. This variant has also been reported in ClinVar (Variation ID#: 431959) and has been interpreted as VUS by Ambry Genetics and Invitae, and likely pathogenic by GeneDx. This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 204 and leads to a premature termination codon 63 amino acids downstream. This alteration occurs within the last exon and is more likely to escape nonsense mediated decay (NMD) and result in a truncated protein. Loss of function of the GAMT gene is an established disease mechanism in autosomal recessive cerebral creatine deficiency syndrome. In summary, the clinical significance of the p.Arg204GlufsTer63 variant is uncertain. ACMG/AMP Criteria applied: PVS1_moderate, PM3_supporting, PM2_supporting (Richards 2015).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation Abbrev="ACMG, 2015" Type="practice guideline">
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GAMT" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NM_000156.6:c.609dup</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000019.10:g.1397462dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0000456" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10607670</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4970004" SubmissionDate="2022-06-23" DateLastUpdated="2022-07-09" DateCreated="2022-07-09">
        <ClinVarSubmissionID localKey="601240.0006_CEREBRAL CREATINE DEFICIENCY SYNDROME 2" title="GAMT, 1-BP DUP, 609G_CEREBRAL CREATINE DEFICIENCY SYNDROME 2" />
        <ClinVarAccession Accession="SCV002540587" DateUpdated="2022-07-09" DateCreated="2022-07-09" Type="SCV" Version="1" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-06-23">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In an infant with cerebral creatine deficiency syndrome-2 (CCDS2; 612736), Hart et al. (2021) identified homozygosity for a 1-bp duplication (c.609dupG) in the GAMT gene, predicted to result in a frameshift and extension of the protein beyond the canonical stop site (Arg204GlufsTer63). The mutation was identified by sequencing of the GAMT gene. The patient was initially identified by abnormal newborn screening showing an elevated guanidinoacetate level on a bloodspot. A 6-year-old sib of this patient was noted to have developmental delay, no speech, and hypotonia of unknown etiology; molecular analysis confirmed that the sib was homozygous for the c.609dupG mutation.</Attribute>
              <Citation>
                <ID Source="PubMed">34389248</ID>
              </Citation>
              <XRef DB="OMIM" ID="612736" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GAMT" />
          </GeneList>
          <Name>GAMT, 1-BP DUP, 609G</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">1-BP DUP, 609G</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="601240.0006" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">CEREBRAL CREATINE DEFICIENCY SYNDROME 2</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3896943" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0000456" MappingRef="MONDO">
        <MedGen CUI="C5244016" Name="Cerebral creatine deficiency syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4970004" TraitType="Disease" MappingType="Name" MappingValue="CEREBRAL CREATINE DEFICIENCY SYNDROME 2" MappingRef="Preferred">
        <MedGen CUI="C0574080" Name="Deficiency of guanidinoacetate methyltransferase" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

